Then, we used a combination of fulvestrant and CLI-095 to test the hypothesis that inhibiting TLR4 will enhance the antimetastatic effect of fulvestrant by suppressing NSCLC cell migration, invasion and metastasis. Here, TLR4 is linked to non-small cell lung carcinoma.